EUVIMEDEUVIMED entdecken
Crossref

The Effect of Adrenalectomy on Overall Survival in Metastatic Adrenocortical Carcinoma

Anis Assad iD, Reha-Baris Incesu iD, Simone Morra, Lukas Scheipner, Andrea Baudo iD, Carolin Siech, Mario De Angelis, Zhe Tian, Sascha Ahyai iD, Nicola Longo, Felix K H Chun, Shahrokh F Shariat und 4 weitere

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgae571 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Anis Assad und 15 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec H2X 0A9, Canada. Hauptthemen laut MEDLINE: Adrenalectomy, Adrenocortical Carcinoma, Adrenal Cortex Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Although complete surgical resection provides the only means of cure in adrenocortical carcinoma (ACC), the magnitude of the survival benefit of adrenalectomy in metastatic ACC (mACC) is unknown.

Objective

This work aimed to assess the effect of adrenalectomy on survival outcomes in patients with mACC in a real-world setting.

Methods

Patients with mACC aged 18 years or older with metastatic ACC at initial presentation who were treated between 2004 and 2020 were identified within the Surveillance, Epidemiology, and End Results database (SEER 2004-2020), and we tested for differences according to adrenalectomy status. Intervention included primary tumor resection status (adrenalectomy vs no adrenalectomy). Kaplan-Meier plots, multivariable Cox regression models, and landmark analyses were used. Sensitivity analyses focused on use of systemic therapy, contemporary (2012-2020) vs historical (2004-2011), single vs multiple metastatic sites, and assessable specific solitary metastatic sites (lung only and liver only).

Results

Of 543 patients with mACC, 194 (36%) underwent adrenalectomy. In multivariable analyses, adrenalectomy was associated with lower overall mortality without (hazard ratio [HR]: 0.39; P < .001), as well as with 3 months' landmark analyses (HR: 0.57; P = .002). The same association effect with 3 months' landmark analyses was recorded in patients exposed to systemic therapy (HR: 0.49; P < .001), contemporary patients (HR: 0.57; P = .004), historical patients (HR: 0.42; P < .001), and in those with lung-only solitary metastasis (HR: 0.50; P = .02). In contrast, no statistically significant association was recorded in patients naive to systemic therapy (HR: 0.68; P = .3), those with multiple metastatic sites (HR: 0.55; P = .07), and those with liver-only solitary metastasis (HR: 0.98; P = .9).

Conclusion

The present results indicate a potential protective effect of adrenalectomy in mACC, particularly in patients exposed to systemic therapy and those with lung-only metastases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdrenalectomyAdrenocortical CarcinomaAdrenal Cortex NeoplasmsHumansFemaleMaleMiddle AgedSEER ProgramAdultAgedSurvival RateRetrospective StudiesPrognosisLiver NeoplasmsKaplan-Meier EstimateFollow-Up Studies

Stichwörter der Autor:innen

adrenalectomyadrenocortical carcinomacytoreductive surgerymetastatic

Autor:innen und Institutionen

  • Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec H2X 0A9, Canada.
  • Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, 20246 Hamburg, Germany.
  • Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, 80131 Naples, Italy.
  • Department of Urology, Medical University of Graz, 8036 Graz, Austria.
  • Department of Urology, IRCCS Ospedale Galeazzi-Sant'Ambrogio, 20157 Milan, Italy.
  • Department of Urology, IRCCS Policlinico San Donato, 20097 Milan, Italy.

ORCID-Profile: Anis Assad, Reha-Baris Incesu, Andrea Baudo, Sascha Ahyai, Derya Tilki, Alberto Briganti, Fred Saad

Zitieren

APA

Assad, A., Incesu, R. B., Morra, S., Scheipner, L., Baudo, A., Siech, C., De Angelis, M., Tian, Z., Ahyai, S., Longo, N., Chun, F. K. H., Shariat, S. F., Tilki, D., Briganti, A., Saad, F., & Karakiewicz, P. I. (2025). The Effect of Adrenalectomy on Overall Survival in Metastatic Adrenocortical Carcinoma. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae571

Vancouver

Assad A, Incesu RB, Morra S, Scheipner L, Baudo A, Siech C, et al. The Effect of Adrenalectomy on Overall Survival in Metastatic Adrenocortical Carcinoma. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae571

BibTeX
@article{Assad2025,
  author = {Assad, Anis and Incesu, Reha-Baris and Morra, Simone and Scheipner, Lukas and Baudo, Andrea and Siech, Carolin and De Angelis, Mario and Tian, Zhe and Ahyai, Sascha and Longo, Nicola and Chun, Felix K H and Shariat, Shahrokh F and Tilki, Derya and Briganti, Alberto and Saad, Fred and Karakiewicz, Pierre I},
  title = {The Effect of Adrenalectomy on Overall Survival in Metastatic Adrenocortical Carcinoma},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgae571}
}
Kostenlos starten →